30861066
2019 Oct 15
Prolonged courses of isavuconazole (ISA) are increasingly utilized in immunocompromised patients. Toxicities have been reported with long-term use of the other triazoles. We report the first real-life tolerability data in 50 patients with hematologic malignancy receiving â‰¥6 months of ISA. ISA was well tolerated in our ill patient population.
hematologic malignancy; invasive mold infections; isavuconazole; toxicity.
